ResearchNurses.co Signs Contract to Support MS Studies in UK
ResearchNurses.co, a UK-based research nurses provider, has been awarded a contract with Nottingham University Hospitals Research and Innovation Department to provide research nursing services for clinical trials related to multiple sclerosis (MS).
As part of the project, research nurses will work alongside three major pharmaceutical sponsors as well as the MS Society in clinical trials for patients with relapsing-remitting MS and secondary progressive MS.
ResearchNurses.co will be working with some of the country’s leading neurologist consultants and investigators at the hospital including Professor Chris Constantinescu, Dr Bruno Gran and Dr Nikos Evangelou.
Dr Maria Koufali, Deputy Director for Research & Innovation at Nottingham University Hospitals said: “These studies are of huge importance to everyone affected by multiple sclerosis and we are keen to offer them to as many patients as possible. This will ensure patient access to innovative medicines but also improvement of our MS clinical services.
“ResearchNurses.co have been extremely quick and efficient at responding to our needs and have demonstrated that they are able to provide a wide-ranging and reliable service, helping us to ensure the integrity of our trial data as well as ensuring trial participants are comfortable throughout the study.”
Based at Nottingham’s Queens Medical Center, ResearchNurses.co will liaise with key sponsors and investigators to oversee and provide drug infusions and venepuncture, as well as providing processing and monitoring services.
John Illingworth, managing director of ResearchNurses.co added: “Many of our clients require nursing assistance and on-site support, our research nurses have extensive experience in fitting into existing team structures as well as expert knowledge of key protocols allowing them to provide a tailor made service and additional resource where it matters most.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
